Trumpet blowing
Congratulations to Mr Stuart Langridge on his award from OpenUK. He’s a tremendous asset to the Open Source community, but terrible at Dudo. (comments have been disabled for this post to deny the subject a right to reply)
Congratulations to Mr Stuart Langridge on his award from OpenUK. He’s a tremendous asset to the Open Source community, but terrible at Dudo. (comments have been disabled for this post to deny the subject a right to reply)
Fed up of the relaxation of the distancing rules? Has unlimited outdoors exercise caused uncomfortable chafing? Do you want to spend more time in front of a computer screen this weekend? Here’s some games I’ve packaged just for you; all available on the Snap Store for your favourite Linux distribution and ranked in order of…
sc-controller is a neat little utility which allows Linux users to use a Steam Controller to play non-Steam games. I’ve used it for a long time on Ubuntu to play games like Pillars of Eternity from the comfort of my armchair. Sadly, it is built with the now-deprecated python2 technology, and the upcoming 20.04 release…
A mini retrospective on Manic Miner, one of the most iconic games released on the ZX Spectrum. I keep playing it today for good reason.
To celebrate Ubuntu’s 15th birthday, I try my original Warty Warthog disk in a virtual machine (with hilarious consequences)
Congratulations to the medical, physics, dosimetry, tech, radiography and nursing teams at the Oncology department at Raigmore Hospital in Inverness on becoming the first Cancer Centre to offer tattoo-less radiotherapy for breast cancer patients in the NHS. Reducing the stigmata of radiotherapy reduces the stigma of radiotherapy. Hopefully these combinations of surface-guided and image-guided setup…
Men with castrate refractory metastatic prostate cancer which has deficiencies in double stranded DNA repair may have progression of their cancer delayed by Olaparib. This opens up an avenue for bespoke therapy in the management of mCRPC.
Three new studies have shown that recurrence of ovarian cancer can be delayed by giving PARP inhibitors after chemotherapy. These results build on the success of the SOLO1 trial last year, and make a compelling case for treatment. Improvements in life expectancy remain elusive for the time being.
The preliminary results of the RADICALS-RT trial have been presented at the ESMO congress in Barcelona. It appears that many men who have had prostatectomies for prostate cancer can be spared the toxicities of radiotherapy if they have close monitoring of their blood PSA levels.